CAS 982-57-0|Chloramphenicol sodium succinate
| Common Name | Chloramphenicol sodium succinate | ||
|---|---|---|---|
| CAS Number | 982-57-0 | Molecular Weight | 445.184 |
| Density | / | Boiling Point | 716.3ºC at 760mmHg |
| Molecular Formula | C15H15Cl2N2NaO8 | Melting Point | / |
| MSDS | ChineseUSA | Flash Point | 387ºC |
| Symbol | GHS08 | Signal Word | Warning |
Names
| Name | Chloramphenicol sodium succinate |
|---|---|
| Synonym | More Synonyms |
Chloramphenicol sodium succinate BiologicalActivity
| Description | Chloramphenicol succinate sodium is a prodrug of Chloramphenicol, with Haemotoxicity. Chloramphenicol succinate is a competitive substrate and inhibitor of succinate dehydrogenase (SDH) that is the possible reason for its toxicity[1][2][3]. |
|---|---|
| Related Catalog | Research Areas >>OthersSignaling Pathways >>Others >>Others |
| References | [1]. Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet. 1984 May-Jun;9(3):222-38. [2]. Ambekar CS, et al. Chloramphenicol succinate, a competitive substrate and inhibitor of succinate dehydrogenase: possible reason for its toxicity. Toxicol In Vitro. 2004 Aug;18(4):441-7. [3]. Turton JA, et al. Haemotoxicity of chloramphenicol succinate in the CD-1 mouse and Wistar Hanover rat. Hum Exp Toxicol. 1999 Sep;18(9):566-76. |
Chemical & Physical Properties
| Boiling Point | 716.3ºC at 760mmHg |
|---|---|
| Molecular Formula | C15H15Cl2N2NaO8 |
| Molecular Weight | 445.184 |
| Flash Point | 387ºC |
| Exact Mass | 444.010315 |
| PSA | 161.58000 |
| LogP | 0.90410 |
| InChIKey | RPLOPBHEZLFENN-HTMVYDOJSA-M |
| SMILES | O=C([O-])CCC(=O)OCC(NC(=O)C(Cl)Cl)C(O)c1ccc([N+](=O)[O-])cc1.[Na+] |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Human - infant
- DOSE/DURATION :
- 135 mg/kg/3D-I
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - irritability Lungs, Thorax, or Respiration - respiratory stimulation
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 1400 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 1500 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 1530 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 60 gm/kg/5W-I
- TOXIC EFFECTS :
- Liver - other changes Blood - normocytic anemia Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 156 gm/kg/26W-I
- TOXIC EFFECTS :
- Liver - other changes Kidney, Ureter, Bladder - other changes Blood - normocytic anemia
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 6 gm/kg
- SEX/DURATION :
- female 11-14 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 35 gm/kg
- SEX/DURATION :
- male 35 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Paternal Effects - testes, epididymis, sperm duct
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- DOSE :
- 1200 mg/kg
- SEX/DURATION :
- female 7-12 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
MUTATION DATA - TYPE OF TEST :
- Mutation in mammalian somatic cells
- TEST SYSTEM :
- Rodent - mouse Lymphocyte
- DOSE/DURATION :
- 2953 mg/L
- REFERENCE :
- EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 12(Suppl 13),37,1988 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3875 No. of Facilities: 585 (estimated) No. of Industries: 2 No. of Occupations: 10 No. of Employees: 19269 (estimated) No. of Female Employees: 15096 (estimated)
- TYPE OF TEST :
- Mutation in mammalian somatic cells
- TEST SYSTEM :
- Rodent - mouse Lymphocyte
- DOSE/DURATION :
- 2953 mg/L
- REFERENCE :
- EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 12(Suppl 13),37,1988 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3875 No. of Facilities: 585 (estimated) No. of Industries: 2 No. of Occupations: 10 No. of Employees: 19269 (estimated) No. of Female Employees: 15096 (estimated)
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H351 |
| Precautionary Statements | P280 |
| Personal Protective Equipment | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R40 |
| Safety Phrases | 22-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | AB6905000 |
Articles29
More Articles| The myelotoxicity of chloramphenicol: in vitro and in vivo studies: II: In vivo myelotoxicity in the B6C3F1 mouse. Hum. Exp. Toxicol. 17(1) , 8-17, (1998) 1. Chloramphenicol continues to be widely used in many parts of the world despite its known haematotoxicity. Until now, elucidation of the mechanisms involved and any attempt at amelioration of the to... | |
| A commercial enzyme immunoassay method (EMIT) compared with liquid chromatography and bioassay methods for measurement of chloramphenicol. Clin. Chem. 34(9) , 1872-5, (1988) A new enzyme immunoassay method (EMIT; Syva Co.) was compared with conventional high-performance liquid chromatography (HPLC) and agar-diffusion bioassay methods for measurement of chloramphenicol in ... | |
| Chloramphenicol succinate, a competitive substrate and inhibitor of succinate dehydrogenase: possible reason for its toxicity. Toxicol. In Vitro 18(4) , 441-7, (2004) From our previous study [Eur. J. Clin. Pharmacol. 56 (2000) 405] we hypothesized that chloramphenicol succinate (CAPS) may be a competitive substrate for succinate dehydrogenase (SDH). It may be oxidi... |
Synonyms
| (R-(R*,R*))(-)-Butanedioic Acid Mono(2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl) Ester Monosodium Salt |
| Globenicol |
| Chloramphenicol succinate sodium |
| Nevimycin |
| Clorofenicina |
| Solnicol |
| 2,2-Dichloro-N-(b-hydroxy-a-(hydroxymethyl)-p-nitrophenethyl)acetamide a-Ester with Sodium Succinate |
| Chloramphenicol monosuccinate sodium salt |
| protophenicol |
| Betamicetin |
| Nalecin |
| EINECS 213-568-1 |
| MFCD00083598 |
| Levomycetin-Nalcein |
| D-threo-(-)-2,2-Dichloro-N-(b-hydroxy-a-(hydroxymethyl)-p-nitrophenethyl)acetamide a-(Sodium Succinate) |
| Cloromoin |
| butanedioic acid, mono[(2R,3R)-2-[(dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl] ester, monosodium salt |
| CHLORAMPHENICOL,NASUCCINATE |
| Butanedioic acid, mono[(2R,3R)-2-[(2,2-dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl] ester, sodium salt (1:1) |
| Chloramphenicol sodium succinate |
| Sodium 4-{[(2R,3R)-2-[(dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl]oxy}-4-oxobutanoate |
| Mychel-S |
| Sodium chloramphenicol succinate |
